Abstract
Concurrent chemoradiotherapy (CCRT) involves the simultaneous administration of chemotherapy and radiotherapy, in which low-dose chemotherapy enhances the effectiveness of radiotherapy. This combined approach mitigates tumor recurrence and metastasis, ultimately improving patient prognosis. The primary mechanism behind the increased radiosensitivity induced by concurrent chemotherapy involves inhibiting tumor cell repair and the complementary effects of chemotherapy and radiotherapy on different phases of the cell cycle. Despite CCRT application in patients with locally advanced cervical cancer (LACC), the 5-year survival rate remains at 60%. To improve treatment efficacy, a series of exploratory investigations have been conducted, encompassing the integration of targeted therapy, immunotherapy, and utilization of immunomodulatory agents in neoadjuvant protocols preceding CCRT. Although targeted therapies and immunomodulators represent efficacious interventions for LACC management, the scarcity of robust, large-scale evidence-based data necessitates the undertaking of multicenter prospective randomized Phase III clinical trials and dissemination of high-quality publications to elevate the standard of evidence-based medicine. This consensus acts as a valuable resource for clinicians and researchers, highlighting recent seminal evidence-based studies and the evolving landscape of clinical research on targeted and immunomodulatory agents.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call